Indeed, despite having predictors of outcome such as baseline BCLC stage, ECOG-PS, or AFP or evolutionary-events such us early-dermatologic adverse events in patient’s treatment with tyrosine-kinase inhibitors [172,173,174] that could be associated to better outcome, the rate of tumor progression and time to progression would be defined by factors that have not been identified yet. Here, AFP is linked to neoplasm.